Keʻena Honua

Ma Ianuali 22, 2025, ua paʻi ʻo "Nature Medicine" i nā hopena o ka PD-1/CTLA-4 bispecific antibody cadonilimab i hoʻomohala kūʻokoʻa ʻia e Akeso i hui pū ʻia me oxaliplatin a me capecitabine no ka lāʻau lapaʻau mua o ka gastric a i ʻole gastroesophageal j i hoʻomohala ʻole ʻia ma kahi kūloko a metastatic paha.E heluhelu hou aku»

Ma Ianuali 8, 2025, ua ʻāpono ka National Medical Products Administration (NMPA) o Kina i ka PADCEVTM (enfortumab vedotin) i hui pū ʻia me KEYTRUDA (pembrolizumab) no nā poʻe maʻi makua me ka maʻi ʻaʻai urothelial kūloko a i ʻole metastatic (la/mUC). ʻO ka ʻāpono ʻana o ka NMPA i ka enfortumab vedotin i ka comb...E heluhelu hou aku»

Ma Pepeluali 17, 2025, ua hoʻolaha ʻo Innovent Biologics ua loaʻa i kāna protein fusion antibody bispecific PD-1/IL-2α-bias mua loa, ʻo IBI363, kāna lua o ka Fast Track Designation (FTD) mai ka US Food and Drug Administration (FDA). Pili kēia hoʻolālā i ka mālama ʻana i nā mea hiki ʻole ke ʻoki ʻia, ...E heluhelu hou aku»

Ma Ianuali 16, 2025, ua hoʻolaha ʻo IMPACT ua loaʻa iā Senaparib Capsules (派舒宁®) ka ʻae kūʻai aku ma Kina mai ka National Medical Products Administration (NMPA) ma ke ʻano he monotherapy no ka mālama ʻana i nā maʻi makua me ka epithelial holomua (FIGO Stages III a me IV) ov-grade kiʻekiʻe...E heluhelu hou aku»

Ma Pepeluali 7, 2025, ua hoʻolaha ʻo Sichuan Kelun-Biotech Biopharmaceutical i ka ʻae ʻia ʻana o kāna Cetuximab N01 Injection e ka National Medical Products Administration no ka mālama ʻana i ka maʻi ʻaʻai colorectal metastatic (mCRC) ma Kina. Ua hoʻokumu ʻia ka ʻae ʻia ma kahi noiʻi lapaʻau nui-phase III i hōʻike ʻia...E heluhelu hou aku»

Ma Pepeluali 10, 2025, ua hoʻolaha ʻo CARsgen Therapeutics ua loaʻa i ke kumuhana mua i mālama ʻia me kahi lāʻau lapaʻau allogeneic BCMA CAR-T i hoʻomohala ʻia ma ka paepae THANK-u Plus™, ka pane piha koʻikoʻi (sCR) a me ka maʻi koena liʻiliʻi (MRD) ma ka loiloi Day-28. Hoʻomohala ʻia i loko o ka hale...E heluhelu hou aku»

Ma Ianuali 29, 2025, ua paʻi kahi hui noiʻi Kina i kahi ʻatikala i kapa ʻia ʻo "Neoadjuvant pyrotinib and trastuzumab in HER2 positive breast cancer with no early response (NeoPaTHer): effectiveness, safety, and biomarker analysis of a prospective, multicenter, response adapted study" ma ka...E heluhelu hou aku»

Ma Ianuali 26, 2025, ua hoʻolaha ke Kikowaena no ka Loiloi Lāʻau Lapaʻau (CDE) o ka China National Medical Products Administration ua manaʻo ʻia ka injection LM-108 e hoʻokomo ʻia i loko o ka breakthrough therapy no nā ʻōpū paʻa holomua me ka microsatellite instability (MSI-H) a i ʻole nā ​​​​​​hemahema hoʻoponopono mismatch (dMMR) th...E heluhelu hou aku»

Ma Ianuali 20, ua ʻāpono ka National Medical Products Administration (NMPA) i ka humanized monoclonal antibody tagitanlimab (KL-A167 ma mua) Combination therapy o cisplatin a me gemcitabine no ka mālama mua ʻana i nā maʻi nasopharyngeal carcinoma (NPC) e hana hou ʻia a metastatic paha. ...E heluhelu hou aku»

Ma Ianuali 16, 2025, ua ʻāpono ka National Medical Products Administration (NMPA) o Kina i ka New Drug Application (NDA) o limertinib no ka mālama ʻana i nā poʻe maʻi makua me ka maʻi kanesa māmā non-small cell EGFR T790M i hoʻololi ʻia ma kahi kūloko a i ʻole metastatic (NSCLC). E pili ana iā Limertinib Limertinib ...E heluhelu hou aku»

Ma Ianuali 8, ua hāʻawi ke Center for Drug Evaluation (CDE) o ka National Medical Products Administration (NMPA) o Kina i ka Breakthrough Therapy Designation (BTD) no IBI343, kahi TOPO1i anti-CLDN18.2 ADC maikaʻi loa, ma ke ʻano he monotherapy no ka mālama ʻana i ka CLDN18.2-positive advanced pancr...E heluhelu hou aku»

Ma Ianuali 8, 2025, ua hāʻawi ʻia ʻo 9MW2821 i ka Breakthrough Therapy Designation (BTD) e ke Center for Drug Evaluation (CDE) o ka National Medical Products Administration (NMPA) ma Kina. Hāʻawi ʻia ʻo 9MW2821 me ka toripalimab, kahi antibody monoclonal anti-PD-1, no ka lāʻau lapaʻau-naïve, unresecta...E heluhelu hou aku»